All In Biotech

Drug Trial Radar · NCT05099159

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women

Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Oct 29, 2021

Primary completion

Jun 13, 2023

Study completion Oct 10, 2023

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Oct 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat women who have hot flashes after women have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the menopause. Menopause is when women stop having a menstrual cycle, also called a period. During the menopause, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life. The study treatment, elinzanetant, was developed to treat symptoms caused by hormonal changes. It works by blocking a protein called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. There are treatments for hot flashes in women who have been through the menopause, but may cause medical problems for some people. In this study, the researchers will learn how well elinzanetant works compared to a placebo in women who have been through the menopause and have hot flashes. A placebo looks like a treatment but does not have any medicine in it. To compare these study treatments, the doctors will ask the participants to record information about the participants' hot flashes in an electronic diary. The researchers will study the number of hot flashes the participants have and how severe the hot flashes are. The researchers will look at the results from before treatment, after 4 weeks, and after 12 weeks of treatment. The participants in this study will take two capsules of either elinzanetant or the placebo once a day. The participants who take elinzanetant will take it for 26 weeks. The participants who take the placebo will take it for 12 weeks and then take elinzanetant for the next 14 weeks. During the study, the participants will visit the site approximately 9 times and perform 1 visit by phone. Each participant will be in the study for approximately 36 weeks. The treatment duration will be 26 weeks. During the study, the participants will: * record information about the participants' hot flashes in an electronic diary * answer questions about the participants' symptoms The doctors will: * check the participants' health * take blood samples * ask the participants questions about what medicines the participants are taking and if the participants are having adverse events An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if doctors do not think the adverse events might be related to the study treatments.

Conditions

  • Vasomotor Symptoms Associated With Menopause
  • Hot Flashes

Interventions

  • Elinzanetant (BAY3427080)Drug

    120 mg elinzanetant orally once daily

  • PlaceboDrug

    Matching placebo orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)Time frame: From baseline to Week 4
  2. Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)Time frame: From baseline to Week 12
  3. Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)Time frame: From baseline to Week 4
  4. Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)Time frame: From baseline to Week 12

Locations

113 sites in 12 countries. Site status is shown where the registry gives one.

  • Accel Research Sites | Cahaba Medical Care - Birmingham, AL

    Birmingham, Alabama

  • Women's Health Alliance of Mobile

    Mobile, Alabama

  • Onyx Clinical Research - Peoria

    Peoria, Arizona

  • Lynn Institute of the Ozarks

    Little Rock, Arkansas

  • National Institute of Clinical Research - Garden Grove

    Garden Grove, California

  • Clinical Trials Research - Lincoln

    Lincoln, California

  • Torrance Clinical Research Institute, Inc. | Lomita, CA

    Lomita, California

  • Women's Health Care Research | San Diego, CA

    San Diego, California

  • Advanced Women's Health Institute | Denver Office, Greenwood Village, CO

    Greenwood Village, Colorado

  • Physicians' Research Options, LLC | Red Rocks OBGYN

    Lakewood, Colorado

  • Helix Biomedics, LLC

    Boynton Beach, Florida

  • Clinical Research of West Florida | Clearwater, FL

    Clearwater, Florida

  • Sweet Hope Research Specialty, Inc. - Miami Lakes

    Hialeah, Florida

  • Ocean Blue Medical Research Center, Inc | Miami Springs, FL

    Miami Springs, Florida

  • Suncoast Clinical Research Inc. | Pasco

    New Port Richey, Florida

  • Sensible Healthcare, LLC

    Ocoee, Florida

  • Clinical Research of West Florida | Tampa, FL

    Tampa, Florida

  • Fellows Research Alliance, Inc | Savannah, GA

    Savannah, Georgia

  • Family Care Research | Boise, ID

    Boise, Idaho

  • Leavitt Clinical Research | Idaho Falls, ID

    Idaho Falls, Idaho

  • University of Chicago | Laboratory of Dr. Al-Hendy

    Chicago, Illinois

  • AMR - Chicago

    Oak Brook, Illinois

  • Clinical Trials Management | Northshore Office

    Covington, Louisiana

  • Tandem Clinical Research | Marrero, LA

    Marrero, Louisiana

  • Ob and Gyn Physicians MidAtlantic - SKYCRNG

    Oxon Hill, Maryland

  • Genesis Clinical Research and Consulting, LLC

    Fall River, Massachusetts

  • Saginaw Valley Medical Research Group, LLC | Saginaw, MI

    Saginaw, Michigan

  • Metro Jackson OBGYN | Jackson, MS

    Jackson, Mississippi

  • R. Garn Mabey Jr. M.D. Gynecology

    Las Vegas, Nevada

  • Capital Health | Capital Health OBGYN Lawrenceville

    Lawrenceville, New Jersey

  • Columbia University Medical Center

    New York, New York

  • Eastern Carolina Women's Center | New Bern, NC

    New Bern, North Carolina

  • Unified Women's Clinical Research | Raleigh, NC

    Raleigh, North Carolina

  • OHSU Hospital - OB-GYN - Women's Health Research Unit

    Portland, Oregon

  • UPMC Magee-Women's Hospital - Gynecology

    Pittsburgh, Pennsylvania

  • Tribe clinical Research LLC | Greenville, SC

    Greenville, South Carolina

  • Medical Research Center of Memphis | Memphis, TN

    Memphis, Tennessee

  • Research Memphis Associates, LLC | Memphis, TN

    Memphis, Tennessee

  • Austin Regional Clinic | ARC Kelly Lane

    Austin, Texas

  • DiscoveResearch, Inc.

    Bryan, Texas

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.